ํ์ฟ ๋ก๋ ๋ธ๋กฌํ๋ฌผ
ํ์ฟ ๋ก๋ ๋ธ๋กฌํ๋ฌผ์ ์ฃผ๋ก ์ ์ ๋ง์ทจ์ ๋ณด์กฐ์ ๋ก ์ฌ์ฉ๋๋ **๋นํ๋ถ๊ทน์ฑ ์ ๊ฒฝ๊ทผ ์ฐจ๋จ์ **์ ๋๋ค. **๊ธฐ๊ด ๋ด ์ฝ๊ด**, **๊ธฐ๊ณ์ ํ๊ธฐ** ๋ฐ ๋ค์ํ ์ธ๊ณผ ์์ ์ ์ฉ์ดํ๊ฒ ํ๊ธฐ ์ํด ๊ณจ๊ฒฉ๊ทผ ์ด์์ ์ ๊ณตํฉ๋๋ค. > **์ค์ ์์ ์ฃผ์์ฌํญ**: ํ์ฟ ๋ก๋์ **์งํต, ์ง์ ๋๋ ๊ธฐ์ต ์์ค ํจ๊ณผ๊ฐ ์ ํ ์์ต๋๋ค**. ์์์ด ์๋ ์ํ์์ ๋ง๋น๋๋ ๋์ฐํ ๊ฒฝํ์ ๋ฐฉ์งํ๊ธฐ ์ํด, ์ด ์ฝ๋ฌผ์ ์ฌ์ฉํ๊ธฐ ์ ๊ณผ ์ฌ์ฉํ๋ ๋์ ํ์๋ ์ถฉ๋ถํ ์ง์ ๋ฐ ๋ง์ทจ ์ํ๋ฅผ ์ ์งํด์ผ ํฉ๋๋ค. * ์ฅ๊ธฐ ์์ฉํ ์๋ฏธ๋ ธ์คํ ๋ก์ด๋ ๊ทผ์ก ์ด์์ ์ ๋๋ค. * ๋ค๋ฅธ ์ฝ๋ฌผ์ ๋นํด ์์ฉ ์๊ฐ์ด ๋น๊ต์ ๊ธธ๋ฉฐ(์ฉ๋์ ๋ฐ๋ผ 30-45๋ถ), ์ ์ฅ ๋ฐฐ์ค์ ํฌ๊ฒ ์์กดํฉ๋๋ค. * d-ํฌ๋ณด์ฟ ๋ผ๋ฆฐ๋ณด๋ค 5๋ฐฐ ๊ฐ๋ ฅํ๊ณ ๋ฒ ์ฟ ๋ก๋์ ์ฝ 3๋ถ์ 1 ์ ๋์ ํจ๋ฅ์ ๊ฐ์ง ๊ฒ์ผ๋ก ๊ฐ์ฃผ๋ฉ๋๋ค(์ผ๋ถ ๋ฌธํ์์๋ ๋๋ฌผ์์ ๋๋ฑํ ํจ๋ฅ์ ๊ฐ์ง๋ค๊ณ ์ ์ํจ).
์์ฉ ๊ธฐ์ : Pancuronium acts as a competitive antagonist at the **nicotinic acetylcholine receptors (nAChRs)** located at the **neuromuscular junction (motor endplate)**. * Pancuronium competitively binds to **nAChRs** โ prevents **acetylcholine (ACh)** from binding โ inhibits depolarization of the muscle fiber membrane โ results in flaccid skeletal muscle paralysis. * **Cardiovascular Effects**: Unlike some other neuromuscular blockers, pancuronium has slight vagolytic (anticholinergic) activity at postganglionic **muscarinic receptors** in the heart โ leads to slight increases in heart rate and blood pressure. * It rarely causes histamine release compared to older agents like d-tubocurarine.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- General muscle relaxation ยท 0.044-0.11 mg/kg IV ยท IV ยท as needed ยท higher dose used initially; lower doses required if repeated doses are necessary
- Neuromuscular blockade during anaesthesia ยท 0.025-0.075 mg/kg initially; repeat doses at increments of 0.01 mg/kg ยท IV ยท as needed ยท Duration of action >45 min ยท Initially use a higher dose. Repeated doses may be cumulative and lead to difficulty in antagonism.
- Muscle relaxation ยท 0.1 mg/kg IV ยท IV ยท as needed ยท Dose for rabbits
- As a paralytic during mechanical ventilation ยท 0.05-0.1 mg/kg IV ยท IV ยท lasts about an hour ยท must give sedation as well
- General muscle relaxation ยท 0.044-0.11 mg/kg IV ยท IV ยท as needed ยท higher dose used initially; lower doses required if repeated doses are necessary
- Anesthesia maintenance adjunct (when inhalational agents result in severe hypotension) ยท 0.02-0.04 mg/kg IV ยท IV ยท provides 30-45 minutes of muscle relaxation ยท Used when IV/regional techniques are inadequate to prevent spontaneous movement
- Neuromuscular blockade during anaesthesia ยท 0.025-0.075 mg/kg initially; repeat doses at increments of 0.01 mg/kg ยท IV ยท as needed ยท Duration of action >45 min ยท Initially use a higher dose. Repeated doses may be cumulative and lead to difficulty in antagonism.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Known hypersensitivity to pancuronium or bromides
- Myasthenia gravis (extreme caution or contraindicated)
- Conscious or inadequately anaesthetized animals
- Lack of positive pressure ventilation facilities
- Lack of monitoring equipment (nerve stimulator)
์ด์๋ฐ์
- Slight elevations in cardiac rate and blood pressure
- Hypersalivation (if not pretreated with an anticholinergic agent)
- Prolonged or profound muscular weakness
- Respiratory depression
- Histamine release with resultant hypersensitivity reaction (Very Rare)
- Tachycardia (due to vagolytic effect)
- Prolonged neuromuscular blockade
- Mild hypertension
์ฝ๋ฌผ ์ํธ์์ฉ
- Azathioprine ยท May reverse pancuronium's neuromuscular blocking effects
- Aminoglycosides (e.g., gentamicin) ยท May enhance the neuromuscular blocking activity of pancuronium
- Calcium (IV) ยท May reverse the effects of nondepolarizing neuromuscular blocking agents
- Lincosamides (e.g., clindamycin) ยท May enhance the neuromuscular blocking activity of pancuronium
- Magnesium sulfate or HCl ยท May enhance the neuromuscular blocking activity of pancuronium
- Quinidine ยท May enhance the neuromuscular blocking activity of pancuronium
- Succinylcholine ยท May speed the onset of action and enhance the neuromuscular blocking actions of pancuronium. Do not give pancuronium until succinylcholine effects have subsided.
- Theophylline ยท May inhibit or reverse the neuromuscular blocking action of pancuronium and possibly induce arrhythmias
- Tricyclic Antidepressants (e.g., clomipramine, amitriptyline) ยท Increased risk for cardiac arrhythmias when used with halothane anesthesia
- Volatile anaesthetics ยท Prolonged neuromuscular blockade ยท moderate
- Aminoglycosides ยท Prolonged neuromuscular blockade ยท major
- Clindamycin ยท Prolonged neuromuscular blockade ยท moderate
๋ชจ๋ํฐ๋ง
- Level of neuromuscular blockade (via peripheral nerve stimulation)
- Cardiac rate and rhythm
- Blood pressure
- Adequacy of ventilation and oxygenation
- Peripheral nerve stimulation (e.g., Train-of-Four)
- Heart rate and rhythm
- Respiratory rate, effort, and ventilator parameters (EtCO2, SpO2)
- Body temperature
- Acid-base status
- Serum potassium levels
๊ณผ์ฉ๋
Overdosage increases the risk of **hypotension**, **histamine release**, and **prolonged duration of muscle blockade**. **Treatment:** * **Conservative Support**: Maintain mechanical ventilation, oxygen therapy, and IV fluids until spontaneous breathing returns. * **Pharmacologic Reversal**: Blockade may be reversed by administering an **anticholinesterase agent** (e.g., edrophonium, physostigmine, or neostigmine). * **CRITICAL**: An **anticholinergic** (atropine or glycopyrrolate) MUST be administered prior to or alongside the reversal agent to prevent severe bradycardia and muscarinic side effects. * *Suggested Reversal Protocol*: **Neostigmine** 0.06 mg/kg IV *after* **Atropine** 0.02 mg/kg IV.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.